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For the immune system to respond to a
protein with a ﬁnely tuned, high-afﬁnity anti-
body response, antigen-speciﬁc CD4+ helper
T cells must be activated. Activation of CD4+
T cells is a prerequisite for differentiation along
either the Th1 or Th2 pathway. Activated Th2
cells are strongly associated with the advent of
allergy (Kapsenberg et al. 1998; Mazzarella
et al. 2000; O’Hehir et al. 1991; Van Neerven
et al. 1996). Activation of T cells requires the
recognition via their T-cell receptors of linear
peptide antigens presented in the context of a
cell-surface human leukoctye antigen (HLA)
class II molecule. Any given protein immuno-
gen will contain a discrete number of epitope
regions capable of inducing activation for a
particular HLA class II allele. Interestingly, the
same T-cell epitopes are capable of inducing
either Th1- or Th2-type responses (Van
Neerven et al. 1994), depending on various
environmental and antigen-presenting
cell–speciﬁc factors (Constant and Bottomly
1997; Lanzavecchia and Sallusto 2001). There
is considerable interest in the description of 
T-cell epitopes because the inclusion of helper
epitopes improves the immune response to
synthetic vaccine constructs (Alexander et al.
1994, 1998; del Guercio et al. 1997). Peptide
epitopes have been used in the treatment of
immunologic disorders such as allergy
(Oldﬁeld et al. 2001; Rolland et al. 2000) and
cancer (Kobayashi et al. 2000; Slansky et al.
2000). Finally, manipulation of commonly
promiscuous T-cell epitopes can be used to
create reduced-immunogenicity proteins for
use in a variety of applications (Warmerdam
et al. 2002a, 2002b).
There are currently methods to determine
peptide binding to some HLA class II-DR and
-DQ molecules. Some of these methods mea-
sure the relative strength of the peptide–HLA
interaction using isolated class II molecules
and puriﬁed peptides. Other methods predict
peptide binding to HLA using computer algo-
rithms (Fleckenstein et al. 1999; Sturniolo
et al. 1999; Yu et al. 2002). These predictive
methods are more successful for class I mole-
cules because of the more rigid requirements
for peptide length and anchor residues.
Unfortunately, peptide binding to HLA is not
sufficient to predict the presence of a func-
tional interaction with T cells. There are many
examples in the literature of poorly binding 
T-cell epitopes and of tightly binding peptides
that are not T-cell epitopes (Adorini et al.
1988; Fugger et al. 1996; Lo-Man et al. 1998;
Ma et al. 1999; Velazquez et al. 2001). In
addition, amino acids that flank the epitope
core have been shown to have profound effects
on T-cell activation in the absence of any
effects on HLA binding (Godkin et al. 2001).
We have developed a functional assay that
localizes T-cell proliferative responses to pep-
tide epitopes using human community donor
cells as the test material (Stickler et al. 2000).
The localization of epitopes in our assay is
based on a population approach, in that a
large replicate of community donor responses
is compiled and analyzed for the presence of
an “immunodominant” peptide. Interestingly,
many HLA class II alleles present similar epi-
topes (“promiscuous” T-cell epitopes), a prop-
erty caused by shared binding pockets among
the multitude of HLA class II alleles
(Southwood et al. 1998). We have noted
HLA-DR associations with particular peptide
responses (Stickler et al. 2000) but assume
that our assay largely identifies promiscuous
HLA-DR supertype–associated epitopes.
Our assay was developed to predict
functional T-cell epitopes in a population of
individuals who have not been previously
exposed to the protein under study. This is
important for two reasons. First, many novel
therapeutic and recombinant proteins are
environmentally “new” in that human expo-
sure to these proteins is not detected; there-
fore, methods are needed to predict a priori
immunogenicity. Second, evidence from the
literature suggests that as an immune response
develops, T-cell epitope complexity increases.
T-cell epitopes that “prime” the system can be
completely discrete from secondary epitopes
that arise as the response matures (Muraro et
al. 2000). This is especially pronounced when
studying T-cell clones, where an individual
cloned line may have strict specificity for an
epitope that is not an immunodominant epi-
tope as deﬁned by a pooled T-cell analysis. In
human population–derived data where there
is a known sensitization rate [e.g., the ~1% of
the general population who are veriﬁed sensi-
tive to peanuts (Sicherer and Sampson 2000)],
our results likely expose both the immun-
odominant and the subdominant epitope
regions in the protein of interest. Although
not shown here, immunodominant and sec-
ondary epitopes could be distinguished in the
described assay if the input CD4+ T cells were
separated into naive (CD4+ CD45RO–) and
memory (CD4+ CD45RO+) populations.
We have applied this assay system to the
study of a known food allergen, Brazil nut 2S
storage protein Ber e 1. We also tested two
bacterial endotoxins known to induce in occu-
pationally exposed workers antigen-specific
antibodies (Bernstein et al. 1999) that have
been associated with hypersensitivity reactions
in humans (Ferber 1999; Netting 2000). Our
results suggest that differences in allergenic
potential can be determined using this assay.
Materials and Methods
Protein sequences. The mature 2S storage pro-
tein from Bertholletia excelsazil (Brazil nut)
consists of two small polypeptides, a light
chain of 64 amino acids and a heavy chain of
82 amino acids (accession no. P04403).
Bacillus thuringiensis (Bt) Cry1Ab, the protoxin
sequence from Bt serovar aizawai, consists of a
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[Online 21 January 2003]single 610-amino-acid polypeptide (accession
no. A26461). Cry3Aa, the protoxin sequence
from Bt subspecies san-diego, consists of a 644-
amino-acid polypeptide (accession no.
P07130). Mature protein sequences were used
to design peptides. Signal sequences and other
prosequences were not included.
Peptides. All peptides were purchased from
Mimotopes (San Diego, CA, USA) as multi-
pin syntheses (PepSets) (Maeji et al. 1990).
Peptides were resuspended in dimethyl sulfox-
ide (Sigma, St. Louis, MO) at 1 or 2 mg/mL,
and stored frozen at –70°C until use. Peptides
were synthesized as 15-mers that overlapped by
12 amino acids. The sequence of both the light
and the heavy chain of Ber e 1 were used to
create a 27-peptide-containing set. The
sequence of the light chain is encompassed in
the first six amino acids of the set, and the
heavy chain in the final 21 peptides. The
sequences of Cry1Ab and Cry3Aa were tested
as sets of 200 and 211 peptides, respectively.
Peptide sets for the two Bt proteins were
very large. To facilitate testing, these sets were
tested as pools of two consecutive peptides
per well.
Donor pool. All human blood samples
were obtained from the Stanford University
Blood Center (Palo Alto, CA) or the
Sacramento Medical Foundation (Sacramento,
CA). Each donor was HLA haplotyped for
DRβ1 and DQβ using a low-stringency
sequence-specific primer-polymerase chain
reaction (SSP-PCR) kit from Bio-Synthesis
(Louisville, TX). The HLA-DR and -DQ
expression by our donor pool was found to be
not significantly different from a North
American reference standard (Mori et al. 1997;
data not shown). Our donor pool does show
evidence of slight enrichments for ethnicities
common to the San Francisco Bay area.
Epitope mapping assay. The assay has
been described in detail elsewhere (Stickler et
al. 2000). Brieﬂy, dendritic cells were differ-
entiated in vitro from blood monocytes
largely according to published protocols
(Zhou and Tedder 1996) but with a few
modifications, including the addition of
interleukin-1α and tumor necrosis factor-α
on day 5 of culture. Purified CD4+ T cells
from the dendritic cell donor were cocultured
with dendritic cells and approximately
5 µg/mL of peptide for 5 days. Each peptide
was tested at least in duplicate. For small pep-
tide sets, such as Ber e 1, the peptides were
routinely tested in triplicate. After 5 days,
proliferation was assessed by tritiated thymi-
dine incorporation. Results for each peptide
were averaged. A stimulation index (SI) for
each peptide was calculated by dividing the
average proliferation for a given peptide by
the average proliferation of control wells con-
taining dendritic cells, CD4+ T cells, and
dimethyl sulfoxide in the absence of peptide.
Data analysis of the pooled Bt peptide sets
was based on replication of responses in
neighboring wells rather than between two
separate replicates for each peptide.
Data analysis. A response to a peptide
was tabulated as positive if the SI was > 2.95.
SI values for each donor were compiled for
each peptide set, and the percentages of
responders are reported. The average back-
ground response rate for each peptide set was
calculated by averaging the percentage
response for all of the peptides in the set.
Major epitopes are defined as having a per-
centage response that is 3-fold or more than
the background. Statistical significance was
calculated using Poisson statistics for the
number of responders to each peptide within
the data set. The response to a peptide was
considered significant if the number of
donors responding to the peptide was differ-
ent from the Poisson distribution deﬁned by
the data set with a p < 0.05.
HLA associations. HLA-DR and -DQ
types were analyzed for associations with
responses to defined epitope peptides. We
used a chi-squared analysis with one degree
of freedom. Where an allele was present in
both the responder and nonresponder pools,
a relative risk was calculated.
Results
Epitope map of Brazil nut 2S storage protein.
The epitope mapping assay was performed on
a donor set of 92 community blood bank
donors using peptides describing the heavy and
light chains of Ber e 1 (Figure 1A). The light
chain of Ber e 1 was described by peptides
1–6. The heavy chain was described by pep-
tides 7–27. The overall background response
to the peptides in this set was 4.27%. This
background level is higher than our overall epi-
tope mapping average (average of ~3% over
~20 proteins tested; data not shown). We have
observed that background responses are higher
when testing peptide sets derived from pro-
teins with known human exposure rates (data
not shown). One epitope (peptide 4 corre-
sponding to amino acids 10–24) was found in
the light-chain sequence that met the criterion
of 3-fold the background response to this pep-
tide set, returning a total percent of responders
equal to 18.48%. Three other prominent
regions were found in the heavy-chain protein
at peptide 12 [amino acids 16–30 (9.78%)],
peptide 16 [amino acids 28–42 (7.61%)], and
peptide 20 [amino acids 40–55 (11.96%)] that
encompass a nested set of epitopes in the
heavy-chain polypeptide. The percentage of
responses to epitopes 16–30 and 40–55 are less
than 3-fold (12.8%) but are more than 2-fold
the background rate. The third epitope
(28–42) does not reach 2-fold the background.
Figure 1B shows the distribution of responses
within the Ber e 1 data set. Peptide 4 had the
most responses tabulated, a total of 17 out of
92 tested donors. There were 11 responses to
peptide 20. This response rate to peptide 4 was
highly significant, with p < 0.0001. The
response to peptide 20 was also significant,
with p = 0.02.
HLA associations within the Ber e 1 data
set. The HLA-DR and -DQ types of donors
who responded to peptides 4 (light-chain
amino acids 10–24) and 20 (heavy-chain
amino acids 40–55) were analyzed for the
presence of any statistically signiﬁcant enrich-
ment in HLA subtypes. HLA-DQ2 was sig-
nificantly associated with a nonresponse to
peptide 4 (p = 0.05, relative risk = 0.29).
There was a positive association between the
presence of HLA-DR15(2) and a response to
peptide 20 (p = 0.04, relative risk = 3.0).
Interestingly, the strongest association found
was a positive association between a response
to peptide 12 and the presence of HLA-
DR13 (p = 0.01, relative risk = 4.44).
Epitope map of Cry1Ab. The epitope
mapping assay was performed on a donor set
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Figure 1. Mapping and designation of epitopes in Ber e 1. (A) We tested 92 community donors for reactivity
with 27 15-mer peptides derived from the sequence of the Ber e 1 heavy and light chains. The peptides
overlapped by 12 amino acids. Individual donor responses that reached an SI of > 2.95 were tabulated as
positive. The percentage of the 92-donor pool that responded to each peptide is on the y-axis. The linear
peptide designation is indicated on the x-axis. The location of each prominent peptide is indicated by num-
bers, which correspond to the amino acids of the light- and heavy-chain linear sequences. (B) Distribution
of responses to peptides. The number of donor responses (x-axis) is plotted versus the frequency (y-axis).
One peptide in the Ber e 1 data set accumulated 17 responses (peptide 4), and one accumulated 12
responses (peptide 20).
*Statistically signiﬁcant responses.
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40–55of 48 community blood bank donors using
pooled peptides describing the sequence of Bt
Cry1Ab (Figure 2A). Many peptides were
associated with a 0% donor response. On the
advice of our statistician, we calculated the
background response and determined epitopes
using data only from the peptides that
returned responses. The background rate for
the peptide set was determined to be 2.95%.
This background response is consistent with
our overall average and suggests that our
donor population is not exposed to this pro-
tein at levels that could result in an immune
response. One epitope meeting the 3-fold cut-
off value was detected at peptide 145 [amino
acids 433–447 (10.4%)]. A second prominent
epitope region was noted at amino acid posi-
tions 76–90 (8.33%), but it does not meet the
3-fold cutoff. Figure 2B shows the distribu-
tion of responses to the Cry1Ab peptide set.
Only one response rate was statistically signiﬁ-
cant, at peptide 145, with p = 0.006. HLA
associations were not determined because of
the low number of responding donors.
Epitope map of Cry3Aa. The epitope map-
ping assay was performed on a donor set of 47
community blood bank donors using pooled
peptides describing the sequence of Bt Cry3Aa
(Figure 3A). As seen in the Cry1Ab data set,
many peptides were associated with a 0%
donor response. We calculated the background
response and determined epitopes using data
only from the peptides that returned responses.
The background rate for the peptide set was
determined to be 3.3%. This background
response is consistent with our overall average,
and similarly suggests that this protein is not
encountered immunologically by our donor
population. No peptides reached the 3-fold
above background cutoff value. Two peptides
returned results more than 2-fold the back-
ground, at amino acid positions 118–132
(8.5%) and 139–153 (8.5%).
Figure 3B shows the distribution of
responses to the Cry3Aa peptide set. No
responses were signiﬁcant.
HLA associations were not determined
because of the low number of responding
donors.
Discussion
We tested a known food allergen, Brazil nut
2S storage protein Ber e 1, and two potential
food allergens, Cry1Ab and Cry3Aa, in our
epitope mapping assay. We found that the
Brazil nut protein contained one major
epitope in the light-chain and at least three
more prominent response regions in the
heavy-chain polypeptide sequences compris-
ing a total of 127 amino acids. As a compari-
son, the Cry proteins contained one major
epitope in 610 amino acids (Cry1Ab) and no
major epitopes in 644 amino acids (Cry3Aa).
These data are consistent with the published
information regarding the relative immuno-
genicity of these three proteins.
The human response data compiled for
the Brazil nut protein peptides had a higher
background rate than either of the two Bt Cry
proteins. The background rate for Ber e 1 was
higher than observed for most other proteins
tested by us. This observation is consistent
with protein exposure in our pool of commu-
nity donors. In support of this conclusion, the
background response rates for peptide sets
derived from human papilloma virus proteins
are also high. The background rate declines
with the prevalence of the human papilloma
virus strain tested (data not shown). This
higher rate of background can be explained by
the presence of memory responses to Brazil
nuts and the human papilloma virus proteins.
The epitope mapping assay uses total CD4+ T
cells from our donors that have not been
selected for naive versus memory phenotype.
To test this hypothesis, we are retesting the
Brazil nut peptide set comparing unselected
and CD45RA+ CD4+ T cells (naive CD4+)
from the same individuals to determine
whether the presence of preactivated and/or
memory CD4+ T cells has an effect on the
background rate and the localization and
dominance of T-cell epitopes.
The presentation of specific peptides to
the immune system is controlled by the abil-
ity of processed peptides to bind to the
expressed HLA class II protein. Often, this
binding is promiscuous in that a given pep-
tide can bind to many different HLA class II
molecules. To compile information that may
be useful for predicting the development of
allergies, we determined whether there were
any statistically significant associations
between the presence of particular HLA mol-
ecules and responses to the epitope peptides.
HLA associations have been made using this
assay on other proteins—for example,
Bacillus lentus subtilisin (Stickler et al. 2000;
data not shown). We show here both positive
and negative associations between HLA-DR
and -DQ expression and epitope regions in
the Ber e 1 protein. It would be of interest to
determine if donors carrying these alleles are
enriched in the Brazil nut allergic population.
However, confirmation of these results with
exposed donors is unlikely because the num-
ber of veriﬁed sensitized donors is small.
Our assay is based on CD4+ T-cell
activation by autologous dendritic cells and
15-mer peptides derived from the amino acid
sequence of the protein of interest. We set an
arbitrary value of 3-fold more than the
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Figure 2. Mapping and designation of epitopes in Bt Cry1Ab. (A) We tested 48 community donors for
reactivity with 200 15-mer peptides derived from the sequence of Cry1Ab. The peptides overlapped by
12 amino acids. Individual donor responses that reached an SI of > 2.95 were tabulated as positive. The
percentage of the 48-donor pool that responded to each peptide is on the y-axis. The linear peptide desig-
nation is indicated on the x-axis. The location of the prominent peptide regions in the linear sequence of
the protein is indicated. (B) Distribution of responses to peptides. The number of donor responses (x-axis)
is plotted versus the frequency (y-axis). One peptide in the Cry1Ab data set accumulated ﬁve responses
(peptide 145).
*Statistically signiﬁcant response.
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Figure 3. Mapping and designation of epitopes in Bt Cry3Aa. (A) We tested 47 community donors for
reactivity with 211 15-mer peptides derived from the sequence of Cry3Aa. The peptides overlapped by
12 amino acids. Individual donor responses that reached an SI of > 2.95 were tabulated as positive. The
percentage of the 47-donor pool that responded to each peptide is on the y-axis. The linear peptide desig-
nation is indicated on the x-axis. The location of the prominent peptide regions in the linear sequence of
the protein is indicated. (B) Distribution of responses to peptides. The number of donor responses (x-axis)
is plotted versus the frequency (y-axis). No response was signiﬁcant in this data set.
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139–153background for a proliferative response to a
peptide to be considered positive. Data are
compiled for a number of individuals, and
compiled data are used to pinpoint T-cell epi-
topes that cause activation of T cells in the
largest percentage of the population. An
immunodominant (“major”) epitope is
defined by a percentage of the donor pool
greater than or equal to 3-fold the overall
background response responding to the par-
ticular sequence. This analysis compares
favorably with analysis of data using back-
ground plus three standard deviations as a
cutoff value. However, 3-fold greater than
background indicates more epitopes than the
three-standard-deviations test. Therefore, we
chose to label more regions as immunodomi-
nant epitopes rather than fewer.
During the course of developing this assay
we tested a large number of industrial
enzymes. We veriﬁed our results using CD4+
T-cell samples from individuals known to
have been exposed to the proteins by the pres-
ence of a positive skin-prick test. We veriﬁed
our results for two industrial enzymes by test-
ing both community donors and sensitized
individuals. We are currently validating our
assay against published epitopes for a third
protein (not shown). We tested proteins asso-
ciated with the establishment of tolerance in
human donors (Tindle 2002). However, these
proteins are not an appropriate control for
exogenously encountered proteins, such as
allergens. Regarding food allergens, we have
not tested a nonimmunogenic protein because
we are unaware of a protein that would meet
the criteria as being veriﬁed as “nonallergenic”
in all contexts. In fact, the Cry3Aa protein
may be an appropriate negative control as we
found no CD4+ T-cell epitopes in the protein
sequence, and the protein is not, to our
knowledge, associated with allergy.
Note that this is a technique that will
delineate promiscuously binding immun-
odominant CD4+ T-cell epitopes within the
donor population. Individual responses to pep-
tides may be different from the designated
common epitope regions. Therefore, modiﬁca-
tions to proteins made based on these data will
address epitopes regions for most, but not all,
of the individuals tested. Modifying proteins
based on our method of determining epitopes
will result in the creation of hypoimmuno-
genic, rather than nonimmunogenic, protein
variants. It is critical to appreciate this point.
In summary, we have developed an in vitro
model to predict T-cell epitopes recognized by
human cells. This assay may prove useful in
the selection of potential transgenic products
under consideration for the creation of geneti-
cally modiﬁed plants and foodstuffs. This assay
could be extremely valuable when used in con-
junction with the proposed assessments for
allergenic potential of engineered food crops
(Taylor and Heﬂe 2001).
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